8-K: Yubo Biotech Changes Auditors Amid Going Concern Warning

Yubo International Biotech Limited announced a change in its independent registered public accounting firm, with HHL LLP resigning and HCL, PLLC being appointed, following HHL's prior 'going concern' explanatory paragraph.

Summary

• Yubo International Biotech Limited's independent registered public accounting firm, HHL LLP, resigned on January 13, 2026, with immediate effect.
• HHL LLP's report on the company's financial statements for the year ended December 31, 2024, included an explanatory paragraph regarding the company's ability to continue as a going concern.
• There were no disagreements with HHL on accounting principles, financial statement disclosure, or auditing scope or procedure during the fiscal years ended December 31, 2025, and December 31, 2024, and the subsequent interim period from January 1, 2026, to January 13, 2026.
• No reportable events, as defined in Item 304(a)(1)(v) of Regulation S-K, occurred during the specified periods with HHL.
• The company engaged HCL, PLLC as its new independent registered public accountant on January 13, 2026, with immediate effect, to audit the consolidated financial statements for the year ended December 31, 2025.
• Neither the company nor anyone on its behalf consulted with HCL, PLLC regarding accounting principles or audit opinions prior to its engagement.

Sentiment

Score: 2

Explanation: The sentiment is highly negative due to the explicit 'going concern' warning from the previous auditor, which signals severe financial instability and raises significant doubts about the company's long-term viability. While there were no reported disagreements with the former auditor, the underlying financial health concern overshadows this.

Negatives

• HHL LLP's audit report for the year ended December 31, 2024, contained an explanatory paragraph concerning the company's ability to continue as a going concern, indicating significant financial uncertainty.

Risks

• The company faces substantial uncertainty regarding its ability to continue as a going concern, as highlighted by its former auditor, HHL LLP, in the December 31, 2024, financial statements.

Future Outlook

No specific forward-looking statements or guidance were provided in this filing beyond the engagement of a new auditor for the fiscal year ended December 31, 2025.

Industry Context

An auditor change, especially when preceded by a 'going concern' warning, is a significant event in the biotech industry, which often relies heavily on investor confidence and access to capital. Such a warning can severely impact a company's ability to secure future funding or maintain investor trust, potentially hindering research, development, and operational continuity.

Comparison to Industry Standards

• The inclusion of a 'going concern' explanatory paragraph by an independent auditor is a severe deviation from the financial health typically expected of publicly traded companies in the biotech sector.
• Healthy biotech companies, such as Amgen or Gilead Sciences, consistently receive unqualified audit opinions without 'going concern' modifications, reflecting strong financial positions and operational viability.
• The auditor change itself, while not uncommon, takes on added significance when coupled with a 'going concern' issue, potentially signaling increased scrutiny or underlying financial instability compared to peers.

Corporate Governance

Stakeholder Impact

• Shareholders face increased risk and uncertainty regarding the company's financial stability and future operations due to the 'going concern' warning.
• Potential impact on creditors' confidence and willingness to extend credit, given the doubts about the company's ability to meet its obligations.
• Employees may face job insecurity if the company's financial situation deteriorates further.

Next Steps

• HCL, PLLC will audit the company's consolidated financial statements for the year ended December 31, 2025.

Key Dates

Recommendation

The 'going concern' explanatory paragraph from the previous auditor is a critical red flag, indicating severe financial distress and a high risk of insolvency. While a new auditor has been appointed, this does not mitigate the fundamental financial viability concerns. Investors should consider divesting due to the significant uncertainty and potential for substantial capital loss.

Keywords

Yubo International Biotech, Auditor Change, Going Concern, SEC Filing, 8-K, Biotech, Financial Reporting, Independent Accountant